Disease relevance of Peritoneovenous Shunt

• Peritoneovenous (LeVeen) shunt. Control of renin-aldosterone system in cirrhotic ascites [1].
• Superior vena cava thrombosis as a complication of peritoneovenous shunt [2].
• A superior vena cava syndrome developed in a patient with liver cirrhosis 6 months after implantation of a peritoneovenous shunt [3].
• Chylothorax secondary to obstruction of the superior vena cava: a complication of the LeVeen shunt [4].
• Limited superior vena cava stenosis after peritoneovenous shunt: Dacron graft cavo-auricular anastomosis [5].

High impact information on Peritoneovenous Shunt

• Ascitic pseudocyst obstructing superior vena cava as a complication of a peritoneo-venous shunt [6].
• The insertion of a titanium tip at the venous end of the LeVeen shunt does not prevent obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)[7]
• Insertion of the peritoneovenous shunt to aid in the management of diuretic-resistant ascites resulted in a marked, immediate increase in urine volume and urinary PGE2 excretion in the four patients who were serially evaluated, but natriuresis occurred in only two [8].
• Peritoneovenous shunts (LeVeen) may lead to DIC; bleeding from partially resected liver surfaces is usually a mechanical problem [9].
• Improved renal function and inhibition of renin and aldosterone secretion following peritoneovenous (LeVeen) shunt [10].

Chemical compound and disease context of Peritoneovenous Shunt

• Elevated bilirubin and inability to tolerate rapid increase in vascular volume and excrete the fluid load contraindicate the procedure, but the LeVeen shunt appears to be of significant clinical benefit in selected cases of malignant ascites [11].
• A titanium catheter tip, developed because of this material's thromboresistance, was employed in 13 consecutive cirrhotic patients receiving a LeVeen shunt for intractable ascites [12].
• After insertion of a peritoneovenous shunt in one patient for treatment of refractory ascites, plasma atrial natriuretic peptide, urinary volume and sodium excretion increased, whereas elevated plasma levels of noradrenaline, renin activity and aldosterone decreased markedly [13].

Associations of Peritoneovenous Shunt with chemical compounds

• The physiologic process of the LeVeen shunt is reviewed and we suggest placement of a radiopaque marker into the tubing [14].
• Class III patients have a poor prognosis independent of ethanol intake (all lived less than 5 months, except 1 patients who received a peritoneovenous shunt) [15].
• Leveen shunt visualization without function using technetium-99m macroaggregated albumin [16].

Gene context of Peritoneovenous Shunt

• Nonfunction of a Leveen shunt was diagnosed in a 53-year-old cirrhotic woman by lack of lung visualization following intraperitoneal administration of Tc-99m MAA, despite imaging of the shunt tubing itself [16].

References